Back to Search
Start Over
Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia
- Source :
- Open Medicine, Vol 11, Iss 1, Pp 374-380 (2016)
- Publication Year :
- 2016
- Publisher :
- De Gruyter, 2016.
-
Abstract
- Autoimmune hemolytic anemia (AIHA) is a rare hematologic disease, primarily affecting adults or children with immunodeficiency disease. First-line therapy consists of long course of steroids administration, with an early complete response rate (CRr) of 75-80%, but up to 20-30% of patients requires a second-line therapy. Rituximab is the first choice in refractory old AIHA patients, because of its safety and efficacy (early CRr at 80-90% and at 68% at 2-3 years). For this reason, splenectomy is even less chosen as second-line therapy in elderly, even though laparoscopic technique decreased complication and mortality rates. However, splenectomy can be still considered a good therapeutic option with a CRr of 81% at 35.6 months in patients older than 60 year-old, when rituximab administration cannot be performed.
- Subjects :
- autoimmune hemolytic anemia
splenectomy
elderly
Medicine
Subjects
Details
- Language :
- English
- ISSN :
- 23915463
- Volume :
- 11
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Open Medicine
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.2a7009edab8452c99e607b1d7ac8881
- Document Type :
- article
- Full Text :
- https://doi.org/10.1515/med-2016-0068